Navigation Links
Cranberry-Active Proven to Treat and Prevent Vaginal Infections
Date:4/22/2013

AMSTERDAM, April 22, 2013 /PRNewswire/ --

Dutch Medical Brands receives first European Class IIa Medical Device Status to treat vaginal infections by using cranberry extracts

Instead of traditional treatment with antibiotics or chemical substances, vaginal infections can be treated and prevented by using Cranberry-Active tablets, developed by Dutch company Medical Brands. The company has obtained a European Class IIa Medical Device Status for its patented Cranberry-Active tablet, making it the first and only cranberry-based product in Europe which has a proven medical claim to treat and prevent vaginal infections.

After the successful introduction of Cranberry-Active capsules for the treatment of bladder- and urinary tract infections in 2012, Medical Brands and American company NATUREX-DBS together have introduced their latest development for treatments of vaginal infections.

,,Vaginal Infections are a serious health problem, affecting one of every three women during their lifetime," says Maikel Hendriks, president of Medical Brands. ,,After the first treatment, another 30 percent will suffer from re-occurrence within three months and 80 percent within nine months."

While the claims of other cranberry-based food supplements and pro-biotic vaginal products have been rejected by the European Food and Safety Authority (EFSA), Medical Brands produced studies which clinically showed that the Cranberry-Active treats and prevents vaginal infections. The product can be freely sold as a self-care medical device on the OTC market in all European countries.

Maikel Hendriks: ,,Our Cranberry-Active marketing authorization is the culmination of years of planning, development and clinical investigation. We answer to a growing global push towards safe and natural solutions as the resistance to antibiotics continues to rise."

His company is specialised in developing self-care medical devices without pharmacologic effects. It provides consumers with solutions for everyday diseases without the side effects that most drugs have.

In the Netherlands and Scandinavia the tablet is sold as the Vaginal Infection Tablet by 'i say'. In other countries Medical Brands is still searching for partners to distribute the products.


'/>"/>
SOURCE Medical Brands
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Cranberry-Active démontre sa capacité à traiter et prévenir les infections vaginales
2. Cranberry-Active wirksam zur Behandlung und Vorbeugung vaginaler Infektionen
3. Cranberry Capsule Proven to Cure Bladder Infection
4. Nonin Medical Awarded Novation Contract for Clinically Proven Pulse Oximeters
5. Study Finds Utilizing Integrated Medical and Pharmacy Data Improves Ability to Forecast Use of High-cost Specialty Treatments
6. Study Showed Patients Treated With The miraDry© System Experienced 82 Percent Sweat Reduction On Average
7. OncoSec ElectroChemotherapy Demonstrates Potential as Alternative to Surgery for Treating Head and Neck Cancer
8. Aethlon Medical Note: An Unprecedented Data Point, The Single-Treatment Capture of Hepatitis C Virus (HCV) by the Aethlon Hemopurifier®
9. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
10. Onyx Pharmaceuticals Announces FDA Advisory Committee to Review Carfilzomib for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
11. Accuray Launches First Study to Compare CyberKnife® SBRT to Surgery and IMRT for Treatment of Early-Stage Prostate Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... February 23, 2017 Persistence ... the global market for intraoperative imaging, excerpts from ... at US$ 513.9 million. According to the report, ... on the grounds of increasing adoption of minimally-invasive ... of diagnostic imaging for neurosurgeries. The world,s leading ...
(Date:2/23/2017)... DUBLIN , Feb 23, 2017 Research ... Prosthetic Devices Market Analysis & Trends - Industry Forecast to 2025" ... ... to grow at a CAGR of around 9.2% over the next ... industry report analyzes the market estimates and forecasts for all the ...
(Date:2/23/2017)... , Feb. 23, 2017 MabVax ... oncology drug development company, announces that it has ... Administration (FDA) authorizing the initiation a Phase I ... for pancreatic cancer. MVT-1075 ( 177 Lu-CHX-A?-DTPA-HuMab5B1) is ... MabVax plans to initiate the phase I clinical ...
Breaking Medicine Technology:
(Date:2/23/2017)... CA (PRWEB) , ... February 23, 2017 , ... CALNOC, ... FACP, FACMPE, FACPE, will keynote their upcoming conference – Empowerment, Value and Collaboration – ... the chairman and CEO of the Virginia Mason Health System in Seattle since 2000. ...
(Date:2/23/2017)... ... February 23, 2017 , ... Curemark, LLC announced today that ... of CM-AT in children aged 3-8 with Autism, is now enrolling at three new ... children across the United States. , “There are currently no approved drugs that ...
(Date:2/23/2017)... ... ... Thomas Vas-Don suffered from severe injury due to an ... successfully recover. In “ Origin & Insertion Charts for Massage Therapists ” (published by ... massage, anatomy , trigger points and referral pain patterns . , In ...
(Date:2/22/2017)... (PRWEB) , ... February 22, 2017 , ... ... and lobby of a new healthcare contact center in Georgia, PENETRON Specialty Products ... of the nation’s largest healthcare systems recently invested $51 million to purchase and ...
(Date:2/22/2017)... Raton, FL (PRWEB) , ... February 22, 2017 , ... ... primarily from deer antler velvet, announced its products are coming soon to Amazon.com, the ... Clint and Shelley Thomson as a means to develop an effective natural treatment for ...
Breaking Medicine News(10 mins):